Table 5 Summary of studies that examined the distribution of control status, changes in clinical control and evaluated the predictive value of control
From: COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort
Number of patients Study design | Investigation objective | Study findings | |
|---|---|---|---|
Baloira A et al. [9] (2016) | 481 patients Spanish cross-sectional multicenter study (primary care vs respiratory care) | Distribution of control status | 36.8% of patients were controlled |
Nibber A [9] et al. (2017) | 2788 patients Retrospective observational cohort study | To validate the concept of control Distribution of control status | 4.5% of patients were controlled Time to first exacerbation was longer for controlled patients (p < 0.001) |
Miravitlles M [10] et al. (2018) | 314 patients Multicenter prospective observational study | To validate concept of control Distribution of control status | 32% of patients were controlled |
Soler-Cataluña JJ [8] et al. (2018) | 265 patients Spanish multicenter prospective observational study | To validate “modified” control criteria To evaluate predictive value of control | 61.5% of patients were controlled The time to the first combined event (emergency room visit, hospitalization, or death) was significantly greater in controlled patients (p < 0.001) |
Barrecheguren [31] et al. (2020) | 2044 patients Multicenter double-blind SPARK study | To validate the prospective value of control | 20% of patients were controlled The rate of exacerbations was lower in controlled patients (OR 0.56, p < 0.0001) and time to first exacerbation was significantly delayed |
Miravitlles [32] et al. (2020) | 307 patients International, multicenter study | To validate the concept of control in COPD | 65% of patients were controlled Time to first exacerbation was significantly delayed for controlled patients |
Soler-Cataluña JJ [11] et al. (2020) | 354 patients Prospective multicenter observational study | To compare changes in control over a 3-month period with changes in risk level and GOLD stage | 50.3% of patients were controlled Changes in control over a 3-month period was 29.3% |
Miravitlles M [20] et al. (2020) | 267 patients International multicenter study Follow-up for 18 months | To describe the changes in control status during follow-up (18 months) and the predictive value of control (6 months) | During 18 months of follow-up, 29.8% of patients remained controlled, 16% persistently uncontrolled and the remaining 53.7% changed control status during follow-up |